British Gambit Delayed Second Immunization With COVID-19 Vaccines
The MHRA has authorized the use of the vaccine for adults (18 years of age and older), in a two-dose, “full” dose schedule, with an interval of 4 to 12 weeks between injections. Thus, the regulator did not find the case for using a “half” dose of this vaccine for the first injection sufficiently convincing. At the same time, the allowed interval between injections was significantly extended. The reason for this was the evidence that the protective efficacy of the vaccine in this time interval after the first injection is 73% (95% CI: 49-86%).
«…Having studied evidence on both the Pfizer/BioNTech and Oxford University/AstraZeneca vaccines, the JCVI has advised the priority should be to give as many people in at-risk groups their first dose, rather than providing the required two doses in as short a time as possible…
From today the NHS across the UK will prioritise giving the first dose of the vaccine to those in the most high-risk groups. With 2 vaccines now approved, we will be able to vaccinate a greater number of people who are at highest risk, protecting them from the disease and reducing mortality and hospitalisation…»Поділитися цим: